99 related articles for article (PubMed ID: 30952769)
1. Local Control and Clinical Outcome of High-risk Pediatric Neuroblastoma Patients After Receiving Multimodality Treatment and Helical Tomotherapy.
Chen GY; Cheng JC; Chen YH; Lu MY; Chang HH; Yang YL; Jou ST; Hsu WM; Kuo SH
Anticancer Res; 2019 Apr; 39(4):2207-2215. PubMed ID: 30952769
[TBL] [Abstract][Full Text] [Related]
2. Dose-escalation is needed for gross disease in high-risk neuroblastoma.
Casey DL; Kushner BH; Cheung NV; Modak S; LaQuaglia MP; Wolden SL
Pediatr Blood Cancer; 2018 Jul; 65(7):e27009. PubMed ID: 29469198
[TBL] [Abstract][Full Text] [Related]
3. Real World Experience of Treating Neuroblastoma: Experience from a Tertiary Cancer Centre in India.
Radhakrishnan V; Raja A; Dhanushkodi M; Ganesan TS; Selvaluxmy G; Sagar TG
Indian J Pediatr; 2019 May; 86(5):417-426. PubMed ID: 30778950
[TBL] [Abstract][Full Text] [Related]
4. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
[TBL] [Abstract][Full Text] [Related]
5. Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma.
Casey DL; Kushner BH; Cheung NK; Modak S; LaQuaglia MP; Wolden SL
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):393-400. PubMed ID: 27473818
[TBL] [Abstract][Full Text] [Related]
6. Excellent local control from radiation therapy for high-risk neuroblastoma.
Gatcombe HG; Marcus RB; Katzenstein HM; Tighiouart M; Esiashvili N
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1549-54. PubMed ID: 19211198
[TBL] [Abstract][Full Text] [Related]
7. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease.
Simon T; Hero B; Bongartz R; Schmidt M; Müller RP; Berthold F
Strahlenther Onkol; 2006 Jul; 182(7):389-94. PubMed ID: 16826357
[TBL] [Abstract][Full Text] [Related]
8. Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma.
Pai Panandiker AS; Beltran C; Billups CA; McGregor LM; Furman WL; Davidoff AM
Pediatr Blood Cancer; 2013 May; 60(5):761-5. PubMed ID: 23024112
[TBL] [Abstract][Full Text] [Related]
9. Proton radiotherapy for high-risk pediatric neuroblastoma: early outcomes and dose comparison.
Hattangadi JA; Rombi B; Yock TI; Broussard G; Friedmann AM; Huang M; Chen YL; Lu HM; Kooy H; MacDonald SM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):1015-22. PubMed ID: 22138463
[TBL] [Abstract][Full Text] [Related]
10. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.
Morgenstern DA; Pötschger U; Moreno L; Papadakis V; Owens C; Ash S; Pasqualini C; Luksch R; Garaventa A; Canete A; Elliot M; Wieczorek A; Laureys G; Kogner P; Malis J; Ruud E; Beck-Popovic M; Schleiermacher G; Valteau-Couanet D; Ladenstein R
Pediatr Blood Cancer; 2018 Nov; 65(11):e27363. PubMed ID: 30015396
[TBL] [Abstract][Full Text] [Related]
11. Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement.
Ferris MJ; Danish H; Switchenko JM; Deng C; George BA; Goldsmith KC; Wasilewski KJ; Cash WT; Khan MK; Eaton BR; Esiashvili N
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):806-812. PubMed ID: 28244417
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma.
Gillis AM; Sutton E; Dewitt KD; Matthay KK; Weinberg V; Fisch BM; Chan A; Gooding C; Daldrup-Link H; Wara WM; Farmer DL; Harrison MR; Haas-Kogan D
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):858-64. PubMed ID: 17517478
[TBL] [Abstract][Full Text] [Related]
13. Managing local-regional failure in children with high-risk neuroblastoma: A single institution experience.
Dove AP; Manole BA; Wakefield DV; Cross SJ; Doubrovin M; Shulkin BL; Merchant TE; Davidoff AM; Furman WL; Krasin MJ; Santana VM; Lucas JT
Pediatr Blood Cancer; 2018 Dec; 65(12):e27408. PubMed ID: 30270551
[TBL] [Abstract][Full Text] [Related]
14. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
15. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Moroz V; Machin D; Hero B; Ladenstein R; Berthold F; Kao P; Obeng Y; Pearson ADJ; Cohn SL; London WB
Pediatr Blood Cancer; 2020 Aug; 67(8):e28359. PubMed ID: 32472746
[TBL] [Abstract][Full Text] [Related]
16. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.
Cai J; Pan C; Tang Y; Chen J; Zhou M; Li B; Xue H; Shen S; Gao Y; Zhang A; Tang J
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1327-1335. PubMed ID: 28283783
[TBL] [Abstract][Full Text] [Related]
17. Value of surgical resection in children with high-risk neuroblastoma.
Englum BR; Rialon KL; Speicher PJ; Gulack B; Driscoll TA; Kreissman SG; Rice HE
Pediatr Blood Cancer; 2015 Sep; 62(9):1529-35. PubMed ID: 25810376
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
[TBL] [Abstract][Full Text] [Related]
19. Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.
Bradfield SM; Douglas JG; Hawkins DS; Sanders JE; Park JR
Cancer; 2004 Mar; 100(6):1268-75. PubMed ID: 15022296
[TBL] [Abstract][Full Text] [Related]
20. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
